Experimental evidence in PPHN lamb models supports the efficacy of all these therapeutic approaches, also supporting potential use of emergent therapies, such as sGC activators/stimulators, l-citrulline, ROCK inhibitors, PPAR-γ agonists, rhSOD, antioxidants (such as BH4 analogs), ω-3 LC-PUFAs, 5-HT2A receptor antagonists, and rhVEGF. The gene discussed is PPARG; the disease is persistent fetal circulation syndrome.